Prognostic Value of E-Cadherin Expression and CDH1 Promoter Methylation in Patients With Endometrial Carcinoma

The primary aim of this study is to evaluate the clinical significance of E-cadherin protein expression and the methylation status in CDH1 promoter in endometrial cancer. The expression of E-cadherin and methylation in its promoter region was analyzed, retrospectively, in 152 clinical tissue samples...

Full description

Saved in:
Bibliographic Details
Published in:Cancer investigation 2011-01, Vol.29 (1), p.86-92
Main Authors: Yi, Tie-Zhong, Guo, Jing, Zhou, Lili, Chen, Xing, Mi, Ruo-Ran, Qu, Quan-Xin, Zheng, Jian-Hua, Zhai, Ling
Format: Article
Language:English
Subjects:
Cadherins - analysis
Cadherins - genetics
Carcinoma - chemistry
Carcinoma - genetics
Carcinoma - mortality
Carcinoma - pathology
China
DNA Methylation
Down-Regulation
E-cadherin
Endometrial cancer
Endometrial Neoplasms - chemistry
Endometrial Neoplasms - genetics
Endometrial Neoplasms - mortality
Endometrial Neoplasms - pathology
Female
Gene Expression Regulation, Neoplastic
Humans
Kaplan-Meier Estimate
Methylation
Middle Aged
Neoplasm Invasiveness
Neoplasm Staging
Prognosis
Prognostic
Promoter
Promoter Regions, Genetic
Proportional Hazards Models
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The primary aim of this study is to evaluate the clinical significance of E-cadherin protein expression and the methylation status in CDH1 promoter in endometrial cancer. The expression of E-cadherin and methylation in its promoter region was analyzed, retrospectively, in 152 clinical tissue samples from patients with endometrial lesions. We found that the hypermethylation of CDH1 promoter, which caused low expression of E-cadherin in endometrial cancer, was associated with not only clinicopathological progress of endometrial cancer but also with the overall 5-year clinical survival rate. The findings provide the potential therapeutic and prognostic target molecule for patients with endomethrial cancer.
ISSN:0735-7907
1532-4192
DOI:10.3109/07357907.2010.512603